The role of soluble urokinase-type Plasminogen Activator Receptor (suPAR) in Chronic Kidney Disease

Ade Yonata, Ian Effendi, Zulkhair Ali, Novadian Suhaimi, Suprapti
Nephrology and Hypertension Division, Internal Medicine Department
Faculty of Medicine Universitas Sriwijaya
Mohammad Hoesin Hospital – Palembang

Editor:
Rully M. A. Roesli

Received 3 April 2018, revised 31 August 2018, accepted 15 October 2018, published 1 December 2018

Abstract
Kidney disease affects 800 million children and adults worldwide, and the numbers keep increasing. A better understanding of the pathogenesis in kidney diseases, especially on a biomolecular level, is much needed to identify novel biomarkers and therapeutic targets for kidney diseases. The glomerular filtration barrier comprises endothelial cells, the glomerular basement membrane, and podocytes. The podocyte has a central role in part of the glomerular filtration barrier. The normal functioning of podocytes is particularly important in preventing the heavy proteinuria seen in nephrotic syndrome or diabetic nephropathy, or in the disease process of focal segmental glomerulosclerosis. The podocyte is injured by circulating factors, which finally results in deranged podocyte motility. Soluble urokinase-type plasminogen activator receptor (suPAR) is a circulating form of glycosyl-phosphatidylinositol uPAR domain protein and is known to play a role in the pathogenesis in kidney diseases, specifically focal segmental glomerulosclerosis and diabetic nephropathy. suPAR binds to αvβ3 integrin on podocyte foot processes and causes podocyte structure disorganization leading to glomerular filtration disruption and hence proteinuria. suPAR is also a potential biomarker to predict the incidence of CKD.

Keywords: FSGS, chronic kidney disease, podocyte, diabetic nephropathy, suPAR

Introduction
Chronic kidney disease (CKD) affects 800 million children and adults all over the world. Its prevalence keeps increasing and impacted approximately 8-16% of the world’s population. Patients with CKD are at a high risk of acquiring cardiovascular diseases (CVD) and death. Therefore it is important to identify high-risk patients and give proper treatment for the underlying diseases to prevent future deterioration. This renders an understanding of the pathogenesis of CKD, especially on a biomolecular level, in order to identify novel biomarkers and therapeutic targets.1

One of the proteins being investigated on its role in the pathogenesis of CKD is soluble urokinase-type plasminogen activator receptor (suPAR). The protein is a form of circulating membrane of the glycosyl-phosphatidylinositol uPAR domain. This protein is known to be involved in the pathogenesis of kidney diseases, especially focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN), through interaction with glomerular podocytes. High level of suPAR affects podocytes in the glomerulus causing malformation and structural abnormalities. This article aims to review and elaborate on the latest findings and development of the role of suPAR in CKD pathogenesis and its potential as a biomarker and therapy target in CKD.2-6
suPAR in Focal Segmental Glomerulosclerosis and Diabetic Nephropathy

Focal segmental glomerulosclerosis (FSGS) is the most common histologic finding in adults with nephrotic syndrome in the US. It is known to be caused by podocyte damage. FSGS is marked morphologically by segmental sclerosis in multiple glomeruli and is clinically marked by proteinuria. FSGS can recur in the newly transplanted kidney with a 30% chance in adults and even higher in children. Clinical observations showed FSGS often develop as a de novo disease in kidney donor recipient, and happens immediately after transplantation procedure. To an extent, this leads to the speculation of a circulating etiological factor. Wei et al elucidated in Nature Medicine about an important advancement in FSGS study where there is a presence of a circulating factor involved in the development of FSGS in human and mice, namely suPAR.

suPAR is formed by multiple immune cells after the cleaving of GPI anchors by cytokines such as TNF-α. suPAR enters the glomerulus and binds and activates β3 integrin, one of the main proteins connecting podocyte to the glomerular basal membrane (GBM). TNF-α can also directly activate podocyte αvβ3 integrin and vinculin. Other serum factors can lower SMPDL3b in podocytes, resulting in the activation of αvβ3 through binding of integrin αvβ3-suPAR. Cdc42 and Rac1 can be activated by the signaling of αvβ3-suPAR, and the actin cytoskeleton of the podocyte will transform from its static form into its motile/active form. The increase of podocyte αvβ3 integrin activity will increase the dynamic process of the podocyte foot process, dysregulating the form and filtrating function of the glomerulus, and could manifest as proteinuria.

Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) in Indonesia. DN is usually manifested as glomerular hyperfiltration and microalbuminuria; it then progresses as a glomerular filtration rate disruption and results in ESRD. suPAR has been found to have a role not only in FSGS but also in diabetic kidney diseases, whereas the increase of suPAR affects the glomerular podocyte through the activation of integrin αvβ3. The activation on the diabetic patient’s podocyte then changes the podocyte structures and causes proteinuria. The remaining question is the molecular mechanism of which the hyperglycaemic condition may repress or upregulate the expression of suPAR.

suPAR as a Predictor Biomarker in Kidney Disease

High suPAR concentration level apparently can predict the incidence of CKD in diabetic patients. In a study where the population had multiple risk factors for type 2 diabetes, high level of suPAR in healthy people with predisposing factors of DM can predict the emergence of microalbuminuria, which is an early sign of diabetic nephropathy, years before microalbuminuria appears. Since microalbuminuria is an important predictor for GFR decline, suPAR has an excellent potential in predicting diabetic nephropathy. A study by Hayek et al in 2015 resulted in a breakthrough finding in nephrology, which stated suPAR as a novel potential biomarker for predicting kidney damage progression for CKD a few years in advance from the onset of the disease. Hayek et al found that patients with the higher suPAR level have lower eGFR and higher proteinuria. Risk of CKD is three-fold higher for subjects in the highest quartile of suPAR level. For subjects with very high suPAR level (over 4020 pg / mL), the incidence risk for CKD in 10 years was found in 80% of the samples.

The study by Hayek et al was done on subjects with cardiovascular diseases. A study that showed the role of suPAR as a predictor biomarker in the general population was done by Schulz et al on 5381 samples in Sweden. It was shown that participants in the quartile of highest suPAR levels have a lower mean of eGFR on follow-up compared to those in the quartile of low suPAR. This study further proves that the role of suPAR in kidney diseases is not limited to FSGS and DN.

suPAR as Therapeutic Target

There are not many published studies investigating the role of suPAR as a therapeutic target, either on FSGS or DN, in humans. The latest study in animals is aimed to block the binding of αvβ3 integrin ligand by a mono-
clonal antibody bound to subunit β3 of the αvβ3 integrin. The study showed that targeting of αvβ3 integrin with monoclonal antibody can improve histological changes related to DN in hyperglycaemic pigs. It was also shown to help reduce proteinuria and inhibit protein synthesis associated with DN on diabetic mice’s kidneys. Sateck et al have done clinical research on humans using multimodal therapy, including plasma exchange in FSGS patients. The therapy was shown to reduce recurrence of FSGS, a decrease in suPAR levels and a decrease in β3 integrin activity. A significant proteinuria reduction is also found with this therapy. However, this effect has been shown to be of temporary nature, with a rebound effect of an increase in suPAR level and β3 integrin reactivation, as soon as 4 days after therapy administration. Whether a better clinical outcome will be achieved with a longer period of lower suPAR level is yet to be proven. Latest findings regarding suPAR and its association with CKD has brought to light a new understanding of the mechanisms of FSGS and DN, and increase our chances in predicting CKD.

Conclusion

suPAR is a biomolecule originating from bone marrow myelocytes, an uPAR protein released from myelocyte membranes and circulate in the blood vessels. suPAR has a role in the pathogenesis of FSGS and DN by entering the glomerulus, bound to αvβ3 integrin at the podocyte foot process and changing the podocyte structures by signaling activity, disrupting glomerular filtration, and thus inducing proteinuria. Based on large observational studies, suPAR is also considered as a highly potential candidate as a novel biomarker in predicting CKD.

References